Last reviewed · How we verify

SAR342434 — Competitive Intelligence Brief

SAR342434 (SAR342434) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: APRIL inhibitor (monoclonal antibody). Area: Immunology.

phase 3 APRIL inhibitor (monoclonal antibody) APRIL (A PRoliferation-Inducing Ligand) Immunology Small molecule Live · refreshed every 30 min

Target snapshot

SAR342434 (SAR342434) — Sanofi. SAR342434 is a monoclonal antibody that targets and inhibits APRIL (A PRoliferation-Inducing Ligand) to reduce B cell activation and autoimmune responses.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
SAR342434 TARGET SAR342434 Sanofi phase 3 APRIL inhibitor (monoclonal antibody) APRIL (A PRoliferation-Inducing Ligand)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (APRIL inhibitor (monoclonal antibody) class)

  1. Sanofi · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). SAR342434 — Competitive Intelligence Brief. https://druglandscape.com/ci/sar342434. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: